Septerna: Novo's Investment In Incretin Program Intrigues - One For The Watchlist

Group 1 - Septerna, a San Francisco-based biotech company, completed its IPO in October 2024, raising approximately $331.2 million by issuing 18.4 million shares priced at $18 each [1] - Following the IPO, the stock of Septerna experienced an initial surge, which is a common trend among biotech stocks post-IPO [1] - The investing group Haggerston BioHealth, led by biotech consultant Edmund Ingham, provides insights into key trends and catalysts in the biotech, pharma, and healthcare industries, catering to both novice and experienced investors [1]